CIAM
BNTC icon

Caitong International Asset Management’s Benitec Biopharma BNTC Stock Holding History

Caitong International Asset Management’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$120 Buy
9
+1
+13% +$12 ﹤0.01% 2133
2026
Q1 		$85 Buy
+8
New +$93 ﹤0.01% 1980

Other funds holding BNTC

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return

Caitong International Asset Management's BNTC Position: Q2 2026 in Review

Caitong International Asset Management increased its Benitec Biopharma (BNTC) stake by 13% in Q2 2026, buying an estimated $12 and bringing the position to 9 shares worth $120. The position accounts for ﹤0.01% of the portfolio, ranked #2133.

Caitong International Asset Management first reported a position in BNTC in Q1 2026 and has held it in 2 quarters since. 87 funds tracked by Wall St. Rank hold BNTC as of Q2 2026.

  • Caitong International Asset Management held 9 shares of Benitec Biopharma worth $120 as of Q2 2026.
  • Caitong International Asset Management bought 1 Benitec Biopharma share in Q2 2026, an estimated $12.
  • Benitec Biopharma made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #2133 holding.
  • Caitong International Asset Management first reported a position in Benitec Biopharma in Q1 2026 and has held it in 2 quarters since.
  • 87 funds tracked by Wall St. Rank held Benitec Biopharma as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.